有没有没人知道这个？

Key points:• 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two infusions of Mesoblast’s allogeneic cell therapy remestemcel-L within the first five days under emergency compassionate use at New York City’s Mt Sinai hospital during the period March-April 2020• 75% (9/12) have successfully come off ventilator support within a median of 10 days• These results contrast with only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period1,2• This compassionate use treatment experience has informed the design of the clinical protocol for the randomized, placebo-controlled Phase 2/3 trial of remestemcel-L in ventilator-dependent COVID-19 moderate/severe ARDS patients across North America

https://commsec.api.markitondemand.com/commsec-node-api/1.0/event/document/1410-02228040-74N2OLVBQEFG35I6OFFUN8CVPB/pdf?access_token=wQ7ENi33pZBER0hmUAEaiYFSoCvE

所有跟帖： 

• 这家公司 -buydip?- ♀ (387 bytes) () 05/05/2020 postreply 21:35:48